Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5396504 | 1.00 | DPP4 (0.34) | DPP4DPP7DPP8NPY2RZAP70 | |
| SCHEMBL5460270 | 0.87 | KDM4E (0.33) | — | |
| SCHEMBL5385277 | 0.87 | KDM4E (0.33) | — | |
| SCHEMBL5385281 | 0.87 | KDM4E (0.33) | — | |
| SCHEMBL5396507 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL5397407 | 0.76 | DPP7 (0.34) | DPP4DPP7DPP8NPY2R | |
| Trifluoroacetic Acid SCHEMBL5397425 | 0.76 | DPP7 (0.34) | DPP4DPP7DPP8NPY2R | |
| Trifluoroacetic Acid SCHEMBL5392342 | 0.75 | HDAC4 (0.39) | DPP4DPP7DPP8 | |
| Trifluoroacetic Acid SCHEMBL5392352 | 0.75 | HDAC4 (0.39) | DPP4DPP7DPP8 | |
| SCHEMBL5388113 | 0.71 | PIK3CG (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | DPP4 280/4885DPP7 153/4885DPP8 179/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | DPP4 257/4885DPP7 140/4885DPP8 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.